NCT07534241 Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients
| NCT ID | NCT07534241 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Lahore |
| Condition | Lipid Profile |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2025-10-02 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2025-10-02 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This 12-week RCT investigates the hepatoprotective and immunomodulatory effects of Ganoderma lucidum combined with a probiotic-rich diet in adults with MAFLD, assessing liver enzymes, lipid profile, inflammation, gut microbiota, and oxidative stress. Findings are expected to show dose-dependent improvements in hepatic fat, insulin resistance, and inflammatory markers, potentially reducing reliance on pharmacotherapy in
Eligibility Criteria
Inclusion Criteria: * Adults aged 35-65 years * BMI between 18.5 and 30 kg/m². * Complete Blood Count test ranges, WBC \< 4,000-11,000 cells/µL, RBC Men \< 4.5-6.0 / Women 4.0-5.5 million/µL, Hemoglobin: Men \< 13.5-17.5 / Women 12.0-15.5 g/dL, Platelets \< 150,000-450,000 cells/µL. * Lipid profile test markers (elevated LDL, total cholesterol, or triglycerides less than 150mg/dL high 200-499mg/dL and 500 mg/dL are above high. * Liver function test markers, ALT \> 56 U/L, AST\>40 U/L, ALP\>147 UL. * Inflammatory markers: CRP \>3 mg/L, - IL-6 ≥3 pg/mL, TNF-α ≥8 pg/mL. * Elevated blood sugar levels, or hyperglycemia, refer to a typically above 126 mg/dL, fasting or 200 mg/dL post-meal. Exclusion Criteria: * ● Diagnosed with severe cardiovascular disease, liver failure, or renal impairment. * Pregnant or lactating women. * Individuals currently on statins, ezetimibe, PCSK9 inhibitors, or any other lipid-lowering therapy. * Allergic to mushrooms. * Diagnosed with celiac disease or other chronic gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis). * History of malignancy. * Participation in another clinical trial within the last 3 months.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07534241 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, up to 65 Years, studying Lipid Profile. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07534241 currently recruiting?
Yes, NCT07534241 is actively recruiting participants. Contact the research team at sananoreen.rizwan@gmail.com for enrollment information.
Where is the NCT07534241 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07534241 clinical trial?
NCT07534241 is sponsored by University of Lahore. The trial plans to enroll 102 participants.